Vertex Pharmaceuticals (VRTX)
News
| 7:26AM | Stocks with implied volatility below IV index mean; VRTX GMCR Street Insider |
| 6:18AM | Invest in the Market's Hottest Sector |
| 6:00AM | The 5 Dumbest Things on Wall Street This Week: June 1 |
| 5:30AM | [video] The 5 Dumbest Things on Wall Street: June 1 |
| 5:20 AM | $VRTX 01/06/12 12:25 SHRT@ 62.09015 STP@ 64.68113 1stTRGT@ 47.03779 L50 H60.36 by yodarbel |
| 5:00AM | Vertex Pharmaceuticals Stock Upgraded (VRTX) |
| May 31 | Invest in the Market's Hottest Sector Fool |
| May 31 | The Market Is Wrong About Vertex Fool |
| May 31 | Still think $VRTX goes but it sure is being controlled and manipulated. Think it can challenge yesterday's highs if it can get going. by prostocktrader |
| May 31 | $VRTX hi- sticking with 42 target- don't like what happend- see the coil but coils can go either way by crackheadtrader |
| May 31 | Sure looks like $VRTX still wants to go, big time coiling around the 60+- zone. by prostocktrader |
| May 31 | $VRTX Volume is down significantly.. Isn't it? by saveme |
Profile
Exchange: NASDAQGS Sector: Healthcare Industry: Biotechnology
Vertex Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development and commercialization of breakthrough drugs for a range of serious diseases, including human immunodeficiency virus infection, chronic hepatitis C virus infection, inflammatory and autoimmune disorders, cancer, pain and bacterial infection, independently and with collaborators. Vertex was founded in 1989 by Kevin Kinsella and Larry Bock of Avalon Ventures and Gary Aronson. It is headquartered in Cambridge, Massachusetts.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Vertex Pharmaceuticals is up 13.24% over the last year vs S&P 500 Total Return down 0.41%, Gilead Sciences up 21.01%, and Idenix Pharmaceuticals up 96.52%.
- VRTX Total Returns
- ^SPXTR Total Returns
- GILD Total Returns
- IDIX Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these VRTX related companies
Pro Strategies Featuring VRTX
Did Vertex Pharmaceuticals make it into our Pro Portfolio Strategies?
VRTX Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other VRTX Resources
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| VRTX | 60.04 | -0.14 | -0.23% | 12.63B |
| VRTS | 70.88 | +0.51 | +0.72% | 545.78M |
| VRTB | 1.260 | -0.00 | -0.01% | 16.56M |
| VRTA | 1.10 | -0.04 | -3.51% | 6.974M |
| VRSN | 38.23 | -0.39 | -1.01% | 6.098B |
| VRSK | 47.90 | +0.01 | +0.02% | 7.893B |
| VRS | 1.15 | +0.04 | +3.60% | 60.48M |
| VRNT | 28.72 | -0.32 | -1.10% | 1.116B |
| VRNM | 3.58 | +0.16 | +4.68% | 45.14M |
| VRNG | 3.79 | +0.29 | +8.29% | 23.61M |
